Similar articles for PMID: 30442752

Year	Number of Results
1999	1
2002	2
2003	2
2004	2
2005	1
2006	2
2007	1
2008	1
2009	10
2010	6
2011	5
2012	9
2013	14
2014	13
2015	12
2016	21
2017	21
2018	24
2019	38
2020	57
2021	57
2022	42
2023	12
2024	0

1

⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.

Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, Akhurst TA, Drummond E, Roselt P, Callahan J, Price R, Jeffery CM, Hong E, Noonan W, Herschtal A, Hicks LJ, Hedt A, Harris M, Paterson BM, Donnelly PS. Hicks RJ, et al. J Nucl Med. 2019 Jun;60(6):777-785. doi: 10.2967/jnumed.118.217745. Epub 2018 Nov 15. J Nucl Med. 2019. PMID: 30442752 Free PMC article. Clinical Trial.

2

⁶⁴Cu Treatment Planning and ⁶⁷Cu Therapy with Radiolabeled [⁶⁴Cu/⁶⁷Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry.

Bailey DL, Willowson KP, Harris M, Biggin C, Aslani A, Lengkeek NA, Stoner J, Eslick ME, Marquis H, Parker M, Roach PJ, Schembri GP. Bailey DL, et al. J Nucl Med. 2023 May;64(5):704-710. doi: 10.2967/jnumed.122.264586. Epub 2022 Dec 2. J Nucl Med. 2023. PMID: 36460344 Clinical Trial.

3

Peptide Receptor Radionuclide Therapy with ⁶⁷Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model.

Cullinane C, Jeffery CM, Roselt PD, van Dam EM, Jackson S, Kuan K, Jackson P, Binns D, van Zuylekom J, Harris MJ, Hicks RJ, Donnelly PS. Cullinane C, et al. J Nucl Med. 2020 Dec;61(12):1800-1805. doi: 10.2967/jnumed.120.243543. Epub 2020 May 15. J Nucl Med. 2020. PMID: 32414949 Free article.

4

⁶⁴Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.

Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, Núñez R. Delpassand ES, et al. J Nucl Med. 2020 Jun;61(6):890-896. doi: 10.2967/jnumed.119.236091. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924723 Free article. Clinical Trial.

5

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Zhang J, et al. J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653971 Free PMC article. Clinical Trial.

6

Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.

Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A. Pfeifer A, et al. J Nucl Med. 2012 Aug;53(8):1207-15. doi: 10.2967/jnumed.111.101469. Epub 2012 Jul 10. J Nucl Med. 2012. PMID: 22782315 Free article. Clinical Trial.

7

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, Virgolini IJ. Gabriel M, et al. J Nucl Med. 2009 Sep;50(9):1427-34. doi: 10.2967/jnumed.108.053421. Epub 2009 Aug 18. J Nucl Med. 2009. PMID: 19690033 Free article.

8

Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.

Jois B, Asopa R, Basu S. Jois B, et al. Clin Nucl Med. 2014 Jun;39(6):505-10. doi: 10.1097/RLU.0000000000000429. Clin Nucl Med. 2014. PMID: 24662668

9

[¹⁸F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [⁶⁸Ga]Ga-DOTATATE in neuroendocrine tumour patients.

Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. Pauwels E, et al. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046. doi: 10.1007/s00259-020-04918-4. Epub 2020 Jul 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32617641

10

Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.

Kaewput C, Vinjamuri S. Kaewput C, et al. Nucl Med Commun. 2016 Dec;37(12):1325-1332. doi: 10.1097/MNM.0000000000000591. Nucl Med Commun. 2016. PMID: 27612032

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

295 results

Results by year